Literature DB >> 12427295

Trends in antipsychotic use in a Texas medicaid population of children and adolescents: 1996 to 2000.

Nick C Patel1, Robert J Sanchez, Michael T Johnsrud, M Lynn Crismon.   

Abstract

The purpose of this study was to examine the current trends in prescribing antipsychotics to children and adolescents within the Texas Medicaid Program. Total enrollments of children and adolescents, ranging from infants to 19-year-olds, in the Texas Medicaid Program were determined for each calendar year from 1996 to 2000. Prevalence was defined as the number of children and/or adolescents with at least one Medicaid prescription claim for an antipsychotic per 1,000 enrollees. Trends in prevalence were assessed over a 5-year period using annual descriptive analyses. In addition, total expenditures for antipsychotics were evaluated within this population. Over the 5-year period, an additional 12.25 children and adolescents per 1,000 enrollees (+160%) were prescribed antipsychotics. The prevalence of atypical antipsychotics increased by 13.29 per 1,000 enrollees (+494%) over the same period. In children and adolescents above 2 years of age, the prevalence of antipsychotic use increased in all groups. Antipsychotic usage was more common in children and adolescents between the ages of 10 and 14 years compared to other age groups. Male and female antipsychotic prevalence rates increased during the 5-year period. The increase in total expenditures was related to the increased utilization of atypical antipsychotics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12427295     DOI: 10.1089/104454602760386905

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  17 in total

1.  Recent changes in prescriptions for antipsychotics in children and adolescents.

Authors:  Elisa F Cascade; Amir H Kalali; Joseph V Penn; David Feifel
Journal:  Psychiatry (Edgmont)       Date:  2006-09

Review 2.  Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Tamara Pringsheim; Darren Lam; Heidi Ching; Scott Patten
Journal:  Drug Saf       Date:  2011-08-01       Impact factor: 5.606

3.  Trends, correlates, and disease patterns of antipsychotic use among children and adolescents in Taiwan.

Authors:  Yuan-Chang Hsu; I-Chia Chien; Happy Kuy-Lok Tan; Ching-Heng Lin; Shu-Wen Cheng; Yiing-Jenq Chou; Pesus Chou
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2013-05-08       Impact factor: 4.328

4.  Physical Health Outcomes in Preschoolers with Prior Authorization for Antipsychotics.

Authors:  Yu-Jung Wei; Xinyue Liu; Nikhil Rao; Marie McPherson; Mary Beth Jones; Regina Bussing; Almut G Winterstein
Journal:  J Child Adolesc Psychopharmacol       Date:  2017-07-14       Impact factor: 2.576

5.  Antipsychotic prescribing in youths: a French community-based study from 2006 to 2013.

Authors:  Hélène Verdoux; Elodie Pambrun; Sébastien Cortaredona; Marie Tournier; Pierre Verger
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-01-07       Impact factor: 4.785

6.  The effects of prior authorization policies on medicaid-enrolled children's use of antipsychotic medications: evidence from two mid-Atlantic states.

Authors:  Bradley D Stein; Emily Leckman-Westin; Edward Okeke; Deborah M Scharf; Mark Sorbero; Qingxian Chen; Ka Ho Brian Chor; Molly Finnerty; Jennifer P Wisdom
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-08-21       Impact factor: 2.576

7.  Antipsychotic treatment among youth in foster care.

Authors:  Susan Dosreis; Yesel Yoon; David M Rubin; Mark A Riddle; Elizabeth Noll; Aileen Rothbard
Journal:  Pediatrics       Date:  2011-11-21       Impact factor: 7.124

8.  Child and adolescent psychiatrists' reported monitoring behaviors for second-generation antipsychotics.

Authors:  Angie Mae Rodday; Susan K Parsons; Catherine Mankiw; Christoph U Correll; Adelaide S Robb; Bonnie T Zima; Tully S Saunders; Laurel K Leslie
Journal:  J Child Adolesc Psychopharmacol       Date:  2015-04-28       Impact factor: 2.576

9.  Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders.

Authors:  Michael G Aman; Alexander A Vinks; Bart Remmerie; Erik Mannaert; Yaser Ramadan; Jessica Masty; Ronald L Lindsay; Krista Malone
Journal:  Clin Ther       Date:  2007-07       Impact factor: 3.393

10.  A non-randomized, open study with aripiprazole and ziprasidone for the treatment of aggressive behavior in youth in a community clinic.

Authors:  Leo Bastiaens
Journal:  Community Ment Health J       Date:  2008-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.